

## **Olmesartan and Azilsartan Equal in Safety and Efficacy in Patients With Essential Hypertension.**

Shiga Y, et al. Int Heart J. 2017; 58(3): 416-421.

- Many patients still have high BP after treatment with angiotensin II type 1 (AT<sub>1</sub>) receptor blockers (ARBs).
- In a 3-month prospective randomized clinical trial in 64 hypertensive patients who were treated with ARBs other than azilsartan and olmesartan, it was demonstrated that efficacy (systolic BP, diastolic BP, pulse rate) and safety of azilsartan were similar to those of olmesartan.
- There were no serious changes in biochemical parameters with either azilsartan or olmesartan.

*As per this publication, Olmesartan and Azilsartan  
Demonstrate Equal Safety and Efficacy in Essential  
Hypertension.*